Liver Diseases  >>  Gilotrif (afatinib)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gilotrif (afatinib) / Boehringer Ingelheim
NCT01298063: Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib

Checkmark P1 data - ESMO
Sep 2012 - Sep 2012: P1 data - ESMO
Completed
1
35
Europe
Afatinib
Boehringer Ingelheim
Liver Diseases, Healthy
01/12
 

Download Options